HealthQuiet 37d · day 37
Moderna reports positive Phase 3 topline results for intismeran autogene plus Keytruda
Moderna's individualized therapy combined with pembrolizumab meets Phase 3 goals in adjuvant melanoma, per company update.
What to know
- Moderna announced positive Phase 3 topline results for intismeran autogene plus pembrolizumab in adjuvant melanoma.
- The announcement comes from a Moderna investor-relations blog post; the provided material does not include detailed trial data, endpoints, or independent commentary.
- Engagement on aggregators was minimal, with no comments recorded.
Moderna Trial sponsor and biotech company
The record 2 articles and posts · last 30 days